RU2018129878A - Иммуноглобулин с тандемными fab-фрагментами и варианты его применения - Google Patents
Иммуноглобулин с тандемными fab-фрагментами и варианты его применения Download PDFInfo
- Publication number
- RU2018129878A RU2018129878A RU2018129878A RU2018129878A RU2018129878A RU 2018129878 A RU2018129878 A RU 2018129878A RU 2018129878 A RU2018129878 A RU 2018129878A RU 2018129878 A RU2018129878 A RU 2018129878A RU 2018129878 A RU2018129878 A RU 2018129878A
- Authority
- RU
- Russia
- Prior art keywords
- binding protein
- antibody
- binds
- cdr
- amino acid
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 10
- 108091008324 binding proteins Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 3
- 101000588258 Taenia solium Paramyosin Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (16)
1. Биспецифический связывающий белок, связывающий антиген А и антиген В, содержащий три полипептидных цепи, при этом первая полипептидная цепь содержит в направлении от амино конца к карбоксильному концу или (1) VLa-CL-VHB-CH1-Fc; или (2) VHB-CH1-VLA-CL-Fc, где VLA представляет собой вариабельный домен легкой цепи антитела первого исходного антитела, которое связывает антиген A, CL представляет собой константный домен легкой цепи антитела, VHB представляет собой вариабельный домен тяжелой цепи антитела из второго исходного антитела, которое связывает антиген В, и СН1 представляет собой первый константный домен тяжелой цепи антитела;
указанная вторая полипептидная цепь содержит, в направлении от амино конца к карбоксильному концу. VHA-СН1, где VHA представляет собой вариабельный домен тяжелой цепи первого исходного антитела, которое связывает антиген А, и СН1 представляет собой первый константный домен тяжелой цепи антитела; и указанная третья полипептидная цепь содержит, в направлении от амино конца к карбоксильному концу, VLB-CL, где VLB представляет собой вариабельный домен легкой цепи второго исходного антитела, которое связывает антиген В и CL представляет собой константный домен легкой цепи антитела;
причем указанный биспецифический связывающий белок связывает антигены А и В и содержит вариабельные домены VLA, VHA, VLB, и VHB, содержащие последовательности аминокислот для каждой из трех последовательностей CDR (CDR-1, CDR-2, CDR-3), выбранных из следующих последовательностей:
2. Биспецифический связывающий белок по п. 1, отличающийся тем, что указанный биспецифический связывающий белок связывает антигены А и В и содержит домены VLA, VHA, VLB и VHB, содержащие последовательность аминокислот для VLA, VHA, VLB и VHB, выбранные из группы:
3. Биспецифический связывающий белок по п. 2, отличающийся тем, что указанный связывающий белок связывает антигены А и В и содержит первую, вторую и третью полипептидную цепи, имеющие последовательности аминокислот, выбранные из группы:
4. Связывающий белок с одной или более консервативными заменами аминокислот в связывающем белке по любому из пп. 1-3, обладающий активностью, эквивалентной соответствующему связывающему белку по пп. 1-3 без консервативных замен аминокислот.
5. Фармацевтическая композиция, содержащая связывающий белок по любому из пп. 1-3 и один или более фармацевтически приемлемый носитель.
6. Способ лечения или предотвращения состояния у нуждающегося в этом субъекта, включающий введение указанному субъекту эффективного количества фармацевтической композиции по п. 5.
7. Способ по п. 6, отличающийся тем, что указанное состояние представляет собой воспалительное заболевание, аутоиммунное заболевание, нейродегенеративное заболевание, рак или повреждение спинного мозга.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/073722 | 2016-02-06 | ||
| CN2016073722 | 2016-02-06 | ||
| PCT/US2017/016691 WO2017136820A2 (en) | 2016-02-06 | 2017-02-06 | Fabs-in-tandem immunoglobulin and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018129878A true RU2018129878A (ru) | 2020-03-06 |
| RU2018129878A3 RU2018129878A3 (ru) | 2020-03-27 |
| RU2767329C2 RU2767329C2 (ru) | 2022-03-17 |
Family
ID=59500269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018129878A RU2767329C2 (ru) | 2016-02-06 | 2017-02-06 | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11421028B2 (ru) |
| EP (1) | EP3411412A4 (ru) |
| JP (1) | JP7014724B2 (ru) |
| KR (1) | KR102185867B1 (ru) |
| CN (1) | CN109195993B (ru) |
| AU (1) | AU2017214692B2 (ru) |
| CU (1) | CU24613B1 (ru) |
| IL (1) | IL260937B2 (ru) |
| MX (1) | MX2018009581A (ru) |
| NZ (1) | NZ743881A (ru) |
| RU (1) | RU2767329C2 (ru) |
| TW (1) | TWI738713B (ru) |
| WO (1) | WO2017136820A2 (ru) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3634484A4 (en) * | 2017-06-05 | 2022-01-12 | The Council of the Queensland Institute of Medical Research | A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| WO2019042153A1 (zh) | 2017-09-01 | 2019-03-07 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
| WO2019126399A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| JP7330977B2 (ja) | 2017-12-19 | 2023-08-22 | スロゼン オペレーティング， インコーポレイテッド | Ｗｎｔサロゲート分子及びその使用 |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| CN112004577B (zh) | 2018-03-14 | 2024-11-22 | 湖南思为康医药有限公司 | 用于降低毒性的免疫细胞修饰以及其在过继细胞疗法中的用途 |
| EP4361177A3 (en) | 2018-04-11 | 2024-08-14 | Salubris Biotherapeutics, Inc. | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
| AU2019263850A1 (en) | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| CN120623353A (zh) | 2018-07-05 | 2025-09-12 | 瑟罗泽恩奥普瑞汀公司 | 多特异性wnt替代分子和其用途 |
| EP3820895A4 (en) * | 2018-07-09 | 2022-04-27 | Shanghai Epimab Biotherapeutics Co., Ltd. | EFFICIENTLY EXPRESSED EGFR AND PD-L1 BINDER PROTEINS |
| SG11202103812RA (en) * | 2018-10-17 | 2021-05-28 | Immunome Inc | Exosome-targeting bispecific antibodies |
| WO2020083277A1 (zh) * | 2018-10-22 | 2020-04-30 | 上海一宸医药科技有限公司 | 一种双特异性抗体 |
| WO2020102387A1 (en) * | 2018-11-13 | 2020-05-22 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US20220064337A1 (en) * | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| JP7530362B2 (ja) | 2018-12-21 | 2024-08-07 | カイマブ・リミテッド | 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体 |
| CA3127669A1 (en) * | 2019-01-07 | 2020-07-16 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| CN110272495A (zh) * | 2019-06-11 | 2019-09-24 | 南京华岩生物技术有限公司 | 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20220104033A (ko) * | 2019-11-25 | 2022-07-25 | 아케소 바이오파마, 인크. | 항-pd-1-항-vegfa 이중특이항체, 약학 조성물 및 이의 용도 |
| CN114728065A (zh) * | 2019-11-26 | 2022-07-08 | 上海岸迈生物科技有限公司 | 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 |
| CN114746451A (zh) * | 2019-11-27 | 2022-07-12 | 上海岸迈生物科技有限公司 | TGFβ/PD-L1双特异性结合蛋白 |
| US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| WO2021238932A1 (zh) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| CN114195901A (zh) * | 2020-09-17 | 2022-03-18 | 上海霖羲致企业管理有限公司 | 双特异性重组蛋白及其用途 |
| WO2022087458A1 (en) * | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| US20250136691A1 (en) * | 2021-09-13 | 2025-05-01 | Plantibodies | Genetically modified organism for recombinant protein production |
| JP2025510539A (ja) * | 2022-03-02 | 2025-04-15 | ビオミュネクス・ファーマシューティカルズ | Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK172110B1 (da) | 1988-04-15 | 1997-10-27 | Gen Hospital Corp | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2857516B1 (en) | 2000-04-11 | 2017-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| TWI385180B (zh) | 2003-07-15 | 2013-02-11 | 安美基公司 | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン，インコーポレーテッド | 抗体のヒト化 |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US20050250185A1 (en) | 2003-12-12 | 2005-11-10 | Murphy Andrew J | OGH fusion polypeptides and therapeutic uses thereof |
| RU2429245C2 (ru) | 2004-03-30 | 2011-09-20 | Глаксо Груп Лимитед | Иммуноглобулины |
| US8124085B2 (en) | 2004-05-05 | 2012-02-28 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| WO2006093794A1 (en) | 2005-02-28 | 2006-09-08 | Centocor, Inc. | Heterodimeric protein binding compositions |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| EP2468768A3 (en) | 2005-07-21 | 2012-10-31 | Abbott Laboratories | Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| EP3366702B1 (en) | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| MX2010009669A (es) | 2008-03-06 | 2010-09-22 | Genentech Inc | Terapia de combinacion con antagonistas de c-met y egfr. |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| TW201008580A (en) | 2008-06-03 | 2010-03-01 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| NZ589436A (en) * | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2011032097A1 (en) | 2009-09-14 | 2011-03-17 | Mount Sinai School Of Medicine | Methods for characterizing antibody binding affinity and epitope diversity in food allergy |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| JP6320753B2 (ja) | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| CA2821976A1 (en) | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| WO2012122528A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| WO2012138997A1 (en) | 2011-04-07 | 2012-10-11 | Amgen Inc. | Novel egfr binding proteins |
| CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | 多特异性fab融合蛋白及其使用方法 |
| MY171038A (en) | 2011-08-23 | 2019-09-23 | Roche Glycart Ag | Bispecific antigen binding molecules |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| CA2843158A1 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| NO2802607T3 (ru) * | 2012-01-13 | 2018-03-03 | ||
| SG11201406238UA (en) | 2012-04-05 | 2014-10-30 | Hoffmann La Roche | Bispecific antibodies against human tweak and human il17 and uses thereof |
| ES2700231T3 (es) * | 2012-11-21 | 2019-02-14 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
| CN105189557A (zh) | 2013-03-15 | 2015-12-23 | 默克专利有限公司 | 四价双特异性抗体 |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| RU2652880C2 (ru) | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| WO2015087279A1 (en) * | 2013-12-12 | 2015-06-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US10188742B2 (en) | 2014-03-03 | 2019-01-29 | Kaohsiung Medical University | Bi-specific antibodies and uses thereof |
| US10329556B2 (en) * | 2014-05-13 | 2019-06-25 | Bioatla, Llc | Conditionally active biological proteins |
| WO2015176033A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| ES2979976T3 (es) | 2014-08-04 | 2024-09-27 | Hoffmann La Roche | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| EP3194435A1 (en) | 2014-09-15 | 2017-07-26 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
| EA036985B1 (ru) | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CA3027612A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
| CN114456269A (zh) | 2016-09-21 | 2022-05-10 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| US11111305B2 (en) | 2017-01-09 | 2021-09-07 | Torch Therapeutics | Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex |
-
2017
- 2017-02-06 RU RU2018129878A patent/RU2767329C2/ru active
- 2017-02-06 US US16/075,922 patent/US11421028B2/en active Active
- 2017-02-06 IL IL260937A patent/IL260937B2/en unknown
- 2017-02-06 CU CU2018000084A patent/CU24613B1/es unknown
- 2017-02-06 WO PCT/US2017/016691 patent/WO2017136820A2/en not_active Ceased
- 2017-02-06 EP EP17748342.7A patent/EP3411412A4/en active Pending
- 2017-02-06 MX MX2018009581A patent/MX2018009581A/es unknown
- 2017-02-06 KR KR1020187025176A patent/KR102185867B1/ko active Active
- 2017-02-06 TW TW106103839A patent/TWI738713B/zh active
- 2017-02-06 AU AU2017214692A patent/AU2017214692B2/en active Active
- 2017-02-06 CN CN201780021758.5A patent/CN109195993B/zh active Active
- 2017-02-06 JP JP2018540722A patent/JP7014724B2/ja active Active
- 2017-02-06 NZ NZ743881A patent/NZ743881A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109195993B (zh) | 2022-05-10 |
| CN109195993A (zh) | 2019-01-11 |
| AU2017214692B2 (en) | 2021-11-04 |
| RU2767329C2 (ru) | 2022-03-17 |
| IL260937A (en) | 2018-09-20 |
| IL260937B2 (en) | 2024-07-01 |
| WO2017136820A3 (en) | 2017-09-08 |
| NZ743881A (en) | 2023-11-24 |
| TWI738713B (zh) | 2021-09-11 |
| EP3411412A2 (en) | 2018-12-12 |
| US20230220080A1 (en) | 2023-07-13 |
| WO2017136820A2 (en) | 2017-08-10 |
| TW201731873A (zh) | 2017-09-16 |
| MX2018009581A (es) | 2019-05-06 |
| KR102185867B1 (ko) | 2020-12-02 |
| BR112018015485A2 (pt) | 2018-12-18 |
| US20190233517A1 (en) | 2019-08-01 |
| CU20180084A7 (es) | 2019-05-03 |
| CA3011746A1 (en) | 2017-08-10 |
| JP7014724B2 (ja) | 2022-02-01 |
| JP2019514839A (ja) | 2019-06-06 |
| KR20180104147A (ko) | 2018-09-19 |
| IL260937B1 (en) | 2024-03-01 |
| CU24613B1 (es) | 2022-07-08 |
| RU2018129878A3 (ru) | 2020-03-27 |
| AU2017214692A1 (en) | 2018-08-30 |
| US11421028B2 (en) | 2022-08-23 |
| EP3411412A4 (en) | 2020-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018129878A (ru) | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения | |
| JP2020536532A5 (ru) | ||
| JP2024045121A5 (ru) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| JP2016536322A5 (ru) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2020505001A5 (ru) | ||
| RU2009148597A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2016529229A5 (ru) | ||
| JP2021502984A5 (ru) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| SI2902039T1 (en) | IL-17 antagonistic antibodies | |
| RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) | |
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| RU2017141738A (ru) | Молекулы, нацеленные на систему секреции типа iii | |
| JP2016529213A5 (ru) | ||
| JP2017511152A5 (ru) | ||
| RU2018131560A (ru) | Способы диагностики и лечения злокачественной опухоли с использованием антител, которые связываются с с1-инактиватором, с-реактивным белком и/или компонентом комплемента с4 | |
| AR123509A1 (es) | Anticuerpos anti il1rap (proteína accesoria del receptor de interleucina-1) y composiciones farmacéuticas que los contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |